García-Sanz et al. [10] analyzed exon single nucleotide polymorphisms in 172 MM patients treated with bortezomib and thalidomide and observed development of chemotherapy complications in patients under similar treatment conditions, and the results showed that PLCG2 rs45443101 may be associated with adverse drug reactions. Here, PLCG2 is linked to Miyoshi myopathy.